Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This st ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Deborah Pokrass
Phone: 713.441.4490
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoemboli ... Read more >